

300.1033

## II. LISTING OF THE CLAIMS

1. (Cancelled) A drug packaging system comprising packaging material comprising therein combined prescription drug therapy comprising one or more unit dosage forms of a first drug and one or more unit dosage forms of a second drug, wherein said first and second drug are independently selected from the group consisting of non-steroidal anti-inflammatory drugs, proton pump inhibitors, calcium channel blockers, angiotensin converting enzyme (ACE) inhibitors, anti-depressants, selective serotonin reuptake inhibitors, antihistamines, decongestants, biguanides, sulfonylureas, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, anti-epileptic, and anti diabetics.

B 2. (Cancelled) A drug packaging system comprising packaging material comprising therein combined prescription drug therapy comprising one or more unit dosage forms of a first drug and one or more unit dosage forms of a second drug, wherein at least one of said first or second drug are selected from the group consisting of non-steroidal anti-inflammatory drugs, calcium channel blockers, angiotensin converting enzyme (ACE) inhibitors, anti-depressants, selective serotonin reuptake inhibitors, antihistamines, decongestants, biguanides, sulfonylureas, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, anti-epileptic, and anti diabetics.

3. (Amended) A drug packaging system comprising packaging material comprising therein combined prescription drug therapy comprising:

unit dosage forms containing lansoprazole or a pharmaceutically acceptable salt thereof ~~one or more unit dosage forms of a first drug and;~~

unit dosage forms containing naproxen or a pharmaceutically acceptable salt thereof; ~~and one or more unit dosage forms of a second drug, wherein said first and second drug are independently selected from the group consisting of antibiotics and anti-ulcer agents selected from the group consisting of H2 antagonists, antacids, bismuth compounds, prostaglandins, carbenoxolone and anticholinergic agents~~

a blister package comprising:

300.1033

(a) a first set of rupturable substrates and a layer forming blisters over each of the rupturable substrates; each of the blisters containing one unit dosage form of lansoprazole or pharmaceutically acceptable salt thereof, and

(b) a second set of rupturable substrates and a layer forming blisters over each of the rupturable substrates; each of the blisters containing one unit dosage form of naproxen or a pharmaceutically acceptable salt thereof.

4. (Cancelled) The drug packaging system of claim 1 wherein said first drug comprises a nonsteroidal anti-inflammatory drug and said second drug comprises a proton pump inhibitor.

5. (Cancelled) The drug packaging system of claim 4 wherein said proton pump inhibitor is omeprazole, lansoprazole, esomeprazole, pantoprazole, isomers, enantiomers or pharmaceutically acceptable salts thereof.

6. (Amended) The drug packaging system of claim 4 wherein each unit dosage form is independently selected from the group consisting of a tablet, capsule, gel cap, and a caplet.

7. (Cancelled) The drug packaging system of claim 4 wherein said non-steroidal anti-inflammatory drug is naproxen, diclofenac, sulindac, oxaprozin, diflunisal, aspirin, piroxicam, indomethacin, etodolac, ibuprofen, fenoprofen, ketoprofen, mefenamic acid, nabumetone, tolmetin, ketorolac, or any pharmaceutically acceptable salt thereof.

8. (Cancelled) The drug packaging system of claim 4 wherein said non-steroidal anti-inflammatory drug is diclofenac or a pharmaceutically acceptable salt thereof.

9. (Cancelled) The drug packaging system of claim 4 wherein said proton pump inhibitor is omeprazole.

300.1033

10. (Cancelled) The drug packaging system of claim 4 wherein each said unit dosage form is a daily dose for a human patient.

11. (Cancelled) The drug packaging system of claim 1 wherein said system is configured as a blister package comprising: a) a rupturable substrate b) a layer forming one or more blisters over the rupturable substrate; wherein each of the one or more blisters contain one or more unit dosage forms.

12. (Cancelled) The drug packaging system of claim 11 wherein said first drug is a non-steroidal anti-inflammatory drug and said second drug is a proton pump inhibitor.

B)

13. (Cancelled) The drug packaging system of claim 11 wherein said proton pump inhibitor is omeprazole.

14. (Cancelled) The drug packaging system of claim 11 wherein said non-steroidal anti-inflammatory drug is diclofenac.

15. (Cancelled) The drug packaging system of claim 1 wherein said system comprises a plurality of blister packs contained within a single package.

16. (Amended) The drug packaging system of claim ~~1~~ 3 wherein said system comprises unit doses for up to 28 days.

17. (Amended) The drug packaging system of claim ~~1~~ 3 wherein said system comprises unit doses for 7-14 days.

18. (Cancelled) The drug packaging system of claim 1 wherein said system comprising one or more dosage forms of a third drug.

19. (Amended) A method of treating a disease or condition treatable by combined administration of more than one medicament, said method comprising:

(a) arranging providing a drug packaging system of comprising unit dosage forms containing lansoprazole or a pharmaceutically acceptable salt thereof; and

unit dosage forms containing naproxen or a pharmaceutically acceptable salt thereof; into

a blister package comprising:

(i) a first set of rupturable substrates and a layer forming blisters over each of the rupturable substrates; each of the blisters containing one unit dosage form of lansoprazole or pharmaceutically acceptable salt thereof; and

(ii) a second set of rupturable substrates and a layer forming blisters over each of the rupturable substrates; each of the blisters containing one unit dosage form of naproxen or a pharmaceutically acceptable salt thereof;

to form a drug packaging system one or more unit dosage forms of a first drug and one or more unit dosage forms of a second drug wherein said first and second drug are independently selected from the group consisting of non-steroidal anti-inflammatory drugs, proton pump inhibitors, calcium channel blockers, angiotensin converting enzyme (ACE) inhibitors, anti-depressants, selective serotonin reuptake inhibitors, antihistamines, decongestants, biguanides, sulfonylureas, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, anti-epileptic, and anti-diabetics;

(b) rupturing one or more substrates to dispense one or more unit doses from the drug packaging system; and

(c) administering said one or more dispensed dosage forms to a human patient first drug and said second drug.

20. (Original) The method of claim 19 which provides therapy for 1-28 days.

21. (Cancelled) The drug packaging system of claim 1 wherein said first drug comprises a nonsteroidal anti-inflammatory drug and said second drug comprises a proton pump inhibitor and wherein said packaging system is perforated to allow the separation of at

300.1033

least one discreet dosage of said first drug and said second drug while leaving the remaining dosage units intact.

Please add the following new claims:

22. (New) The drug packaging system of claim 3, wherein the unit dosage forms containing lansoprazole or a pharmaceutically acceptable salt thereof are capsules.

23. (New) The drug packaging system of claim 3, wherein the unit dosage forms containing naproxen or a pharmaceutically acceptable salt thereof are tablets.

B1 24. (New) The drug packaging system of claim 3, wherein the unit dosage forms containing lansoprazole comprise 15 mg lansoprazole.

25. (New) The drug packaging system of claim 3, wherein the unit dosage forms containing naproxen comprise 500 mg naproxen.

26. (New) The drug packaging system of claim 3, further comprising indicia that provides dosing information for administering the lansoprazole or pharmaceutically acceptable salt thereof and naproxen or pharmaceutically acceptable salt thereof.

27. (New) The drug packaging system of claim 26, wherein the indicia is located on the unit dosage forms.

28. (New) The drug packaging system of claim 26, wherein the indicia is located on the blister layers, rupturable substrates or on other packaging material.

29. (New) The drug packaging system of claim 3, wherein one unit dosage form of lansoprazole or pharmaceutically acceptable salt thereof is suitable for once daily dosing.

300.1033

30. (New) The drug packaging system of claim 3, further comprising indicia that provides information to aid with removal of the unit dosage forms.

31. (New) The drug packaging system of claim 30, wherein the indicia is located on the unit dosage forms.

32. (New) The drug packaging system of claim 30, wherein the indicia is located on the blister layers, rupturable substrates or on other packaging material.

33. (New) A drug packaging system comprising packaging material comprising therein combined prescription drug therapy comprising:

unit dosage forms containing lansoprazole or a pharmaceutically acceptable salt thereof;

unit dosage forms containing an NSAID base or a pharmaceutically acceptable salt thereof; and

a blister package comprising:

(a) a first set of rupturable substrates and a layer forming blisters over each of the rupturable substrates; each of the blisters containing one unit dosage form of lansoprazole or pharmaceutically acceptable salt thereof, and

(b) a second set of rupturable substrates and a layer forming blisters over each of the rupturable substrates; each of the blisters containing one unit dosage form of said NSAID base or pharmaceutically acceptable salt thereof.